De-risking Preclinical Molecules

Argenta has comprehensive capability to support the early assessment and selection of robust pre-clinical molecules, including biomarkers, PK/PD, pharmaceutics, safety and process chemistry provisions. Drug discovery organisations can access all of our technologies through our integrated service and take advantage of our expertise and advice, along with a battery of capabilities. Use our integrated service on your internal drug discovery projects to help identify your most robust molecules and advance these to pre-clinical candidates faster.

• PK/PD
  Bioanalysis, PK/PD Analysis & Modelling, Metabolite Identification and PK profiling
• Biomarker Identification
  Transferring research success into clinical success
• Early Safety Assessment
• Pharmaceutics
  Analytics & Structural Analysis, Physical Property Measurement, Solubility & Dissolution, Polymorphism Screening, Salt Screening and API/IMP Stability Screening
• Process & Scale-up Chemistry
  Translating research routes into scaleable processes

For more information on our pre-clinical candidate de-risking capabilities please contact us.